Click Here for the Guidance

Their guidance aims to help clinicians manage patients who are currently on a medicine that requires monitoring during the COVID-19 pandemic.

The objective is to both protect patients from unnecessary health care visits and help preserve capacity in primary care. 

Overall, they recommend that drug monitoring during the COVID-19 pandemic is prioritised for patients that will gain most benefit, i.e.:

  • Those at risk of a serious adverse drug event that can be identified through monitoring
  • People taking a Narrow Therapeutic Index drug during a phase when intensive monitoring is still required (e.g. upon initiation)
  • Patients who have recently had an illness that may have impacted on how their drug works

Their advice is not intended as a definitive treatment strategy

They have provided advice on factors to consider when making monitoring decisions during COVID-19.

Our advice on individual medicines is below.  We’ll also shortly be adding all our individual medicines advice as a word document for local adaptation.

Azathioprine, leflunomide, mercatopurine, and methotrexate

Sulfasalazine

Hydroxychloroquine

Ciclosporin

Penicillamine

Warfarin

Lithium

Clozapine

The above pages are captured in the following word file and can be used for local adaptation

Guidance on the management of drugs requiring monitoring during COVID-19